Myriad Genetics MYGN Share-Based Payment Award Options Outstanding - Number
Share-Based Payment Award Options Outstanding - Number at other companies
Other financials
Where this comes from
Reported directly by Myriad Genetics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.
The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Myriad Genetics's share-based payment award options outstanding - number.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Myriad Genetics's share-based payment award options outstanding - number?
- Myriad Genetics (MYGN) reported share-based payment award options outstanding - number of 700K in Q1 2026.
- How has Myriad Genetics's share-based payment award options outstanding - number changed year-over-year?
- Myriad Genetics's share-based payment award options outstanding - number decreased by 0.0% year-over-year, from 700K to 700K.
- What is the long-term trend for Myriad Genetics's share-based payment award options outstanding - number?
- Over 5 years (2020 to 2025), Myriad Genetics's share-based payment award options outstanding - number has grown at a -33.0% compound annual growth rate (CAGR), from 5.2M to 700K.
- What does share-based payment award options outstanding - number mean?
- This is the total count of stock options granted to employees and directors that remain unexercised at the reporting date. It reflects the total volume of potential equity claims currently held by the workforce. This metric is a key component in calculating fully diluted share counts.